Oncology Business Management | Specialty

The OncLive Oncology Business Management condition center page is a comprehensive resource for news and expert insights on business-focused updates and topics in oncology practices, including diversity efforts, telehealth, gaps in care, payment models, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates and best practices with oncology business management.

Beyond PSA: A Summary Review of Predictive/Prognostic Biomarkers in Prostate Cancer

September 11th 2014

Although prostate cancer (PC) is the most common solid tumor malignancy among men in the Western Hemisphere, disease-specific mortality remains low, primarily due to optimized screening, diagnosis, and treatment.

FDA Approves Pre-Chemo Enzalutamide for mCRPC

September 10th 2014

The FDA has expanded the approval for enzalutamide to include the treatment of men with chemotherapy-naive metastatic castration-resistant prostate cancer.

Dr. Yang Discusses the Future of Lung Cancer Treatment

September 10th 2014

James CH Yang, MD, PhD, from the National Taiwan University Hospital, discusses the future of lung cancer treatment.

Two Webinars Address Oncology Bundled Payments

September 8th 2014

Don't look now but a consensus that bundled payments is the best payment reform strategy is emerging, and it's expected that many pilot and demonstration projects will start soon.

Life After Obamacare

September 8th 2014

If one had to choose a single word to describe the future of Obamacare, it would probably be "uncertain."

Bristol-Myers Squibb Challenges Patent on Merck's Pembrolizumab

September 5th 2014

BMS has filed a lawsuit over Merck's newly approved immunotherapy drug pembrolizumab, contending that the much-heralded PD-1 inhibitor will infringe upon patents that Bristol-Myers holds on the groundbreaking technology.

Where Should Cancer Care Be Delivered and Why?

August 28th 2014

There is a growing chorus that seems to be debating separate issues-340B drug pricing, the sequester, site of service differential, etc. But the debate revolves around a singular issue-where should cancer care be delivered?

FDA Approves Eltrombopag for Severe Aplastic Anemia

August 26th 2014

The FDA has approved eltrombopag as a treatment for patients with severe aplastic anemia following an insufficient response to immunosuppressive therapy.

Increased Medicaid Payments for Office Visits Results in More Screening for Cancer

August 26th 2014

Medicaid patients in states that pay more for office visits had an increased likelihood of being screened for cancer, according to results of a study published in CANCER.

Report Identifies Shortfalls in Medicare Accountability Model

August 25th 2014

How much physicians get paid is increasingly determined by a payment formula that penalizes doctors whose patients are more expensive-even when those higher costs stem from services that other doctors perform says a new report from the Center for Healthcare Quality and Payment Reform.

COME HOME Program Set to Save $33.5M Over 3 Years

August 25th 2014

In an interview with Oncology Business Management, Barbara L. McAneny, MD, explains how the program will address fragmented care, suboptimal outcomes, high costs, and patient dissatisfaction.

Hospitals Snap Up Practices Under 340B Drug Program

August 20th 2014

A federal program originally meant to require drug manufacturers to provide significant discounts for outpatient drugs is increasingly being used by hospitals to acquire private oncology practices.

Using Technology to Improve Patient Fee Collection Rates

August 19th 2014

Although the Affordable Care Act (ACA) made accessibility to health insurance easier, consumers are finding themselves shouldering greater out-of-pocket costs in the form of copayments and deductibles for the care that they receive. Physicians are also feeling the need to collect more fees from more of their patients.

Medicare to Pay Docs for Chronic Care Coordination

August 18th 2014

Starting in January 2015, Medicare will begin paying physicians for the care coordination they provide beneficiaries with chronic conditions.

FDA Approves Bevacizumab for Advanced Cervical Cancer

August 14th 2014

The FDA has approved bevacizumab in combination with paclitaxel and cisplatin or paclitaxel and topotecan as a treatment for patients with persistent, recurrent, or metastatic cervical cancer.

Tripathy Offers Perspective on HER2-Positive Breast Cancer

August 13th 2014

The ever-evolving treatment landscape for patients with HER2-positive breast cancer leaves several questions unanswered regarding therapeutic sequences and whether an optimal standard of care exists.

FDA Approves First DNA-Based CRC Screening Tool

August 12th 2014

The FDA has approved the noninvasive stool-based DNA test Cologuard for the detection of colorectal cancer or cancer precursors in asymptomatic patients at average risk.

Two-Part Series to Explore Use of Biomarkers in GU Cancer Treatment

August 12th 2014

When it comes to the personalized treatment of genitourinary cancers, biomarkers hold an immense amount of promise. Already, there are predictive and prognostic tools available to urologists.

Glycans Emerge as Promising Biomarkers for Early Detection of Many Cancer Types

July 30th 2014

For many years, we in the medical and research communities have tried to use proteins and DNA fragments as disease markers to find cancer early.

Change to Reimbursement Is Coming! Do We Believe It and Are We Ready?

July 29th 2014

I find it striking that some of my colleagues believe the changes in reimbursement that are under consideration in oncology care delivery will be one of many trends that rises dramatically from the ever present background noise only to later fade into oblivion